BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22429766)

  • 1. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Sutcliffe S; Grubb Iii RL; Platz EA; Ragard LR; Riley TL; Kazin SS; Hayes RB; Hsing AW; Andriole GL;
    BJU Int; 2012 Oct; 110(7):1050-9. PubMed ID: 22429766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
    Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
    J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study.
    Fukuta F; Masumori N; Mori M; Tsukamoto T
    BJU Int; 2012 Oct; 110(7):1023-9. PubMed ID: 22233355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial.
    Johnson CC; Hayes RB; Schoen RE; Gunter MJ; Huang WY;
    Am J Gastroenterol; 2010 Dec; 105(12):2646-55. PubMed ID: 20808298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial.
    Carballido J; Fourcade R; Pagliarulo A; Brenes F; Boye A; Sessa A; Gilson M; Castro R
    Int J Clin Pract; 2011 Sep; 65(9):989-96. PubMed ID: 21733048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of BPH and lower urinary tract symptoms in West Africans.
    Chokkalingam AP; Yeboah ED; Demarzo A; Netto G; Yu K; Biritwum RB; Tettey Y; Adjei A; Jadallah S; Li Y; Chu LW; Chia D; Niwa S; Partin A; Thompson IM; Roehrborn C; Hoover RN; Hsing AW
    Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):170-6. PubMed ID: 21912428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physical activity and benign prostatic hyperplasia-related outcomes and nocturia.
    Wolin KY; Grubb RL; Pakpahan R; Ragard L; Mabie J; Andriole GL; Sutcliffe S
    Med Sci Sports Exerc; 2015 Mar; 47(3):581-92. PubMed ID: 25010403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
    Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
    Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
    Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
    Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
    Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
    BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Schenk JM; Calip GS; Tangen CM; Goodman P; Parsons JK; Thompson IM; Kristal AR
    Am J Epidemiol; 2012 Jul; 176(2):156-63. PubMed ID: 22759721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men.
    Sarma AV; Burke JP; Jacobson DJ; McGree ME; St Sauver J; Girman CJ; Lieber MM; Herman W; Macoska J; Montie JE; Jacobsen SJ
    Diabetes Care; 2008 Mar; 31(3):476-82. PubMed ID: 18071006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
    Chung BH; Hong SJ; Cho JS; Seong DH
    BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nocturia in Spanish patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
    Hernández C; Estivill E; Prieto M; Badía X
    Curr Med Res Opin; 2008 Apr; 24(4):1033-8. PubMed ID: 18302812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
    MacDonald R; Tacklind JW; Rutks I; Wilt TJ
    BJU Int; 2012 Jun; 109(12):1756-61. PubMed ID: 22551330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer].
    Hanai T; Matsumoto S; Shouji S; Usui Y; Tang XY; Kato Y; Iguchi M; Uemura H; Terachi T
    Hinyokika Kiyo; 2009 Apr; 55(4):187-91. PubMed ID: 19462822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting.
    Naslund MJ; Gilsenan AW; Midkiff KD; Bown A; Wolford ET; Wang J
    Int J Clin Pract; 2007 Sep; 61(9):1437-45. PubMed ID: 17686091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rising PSA in patients with minor LUTS without evidence of prostatic carcinoma: a missing link?
    van Renterghem K; Van Koeveringe G; Van Kerrebroeck P
    Int Urol Nephrol; 2007; 39(4):1107-13. PubMed ID: 17602307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.